The utilization of recombinant proteins in vaccines is advantageous from a safety perspective, but these proteins often are very poor at inducing an immune response. In this circumstance, the vaccine antigen can be delivered with substances known as adjuvants to increase the magnitude or duration of the immune response. This chapter examines the characteristics of a good adjuvant, the different types of adjuvants currently licensed or under development in the United States and European Union, and what is known about their mechanism of action. Future trends in adjuvant-driven development of specific types of immune responses and development of novel adjuvants for antigen delivery to specific tissues are also discussed.
- Human vaccines
- Pathogen recognition receptors
- Pathogen-associated molecular patterns
- Veterinary vaccines
ASJC Scopus subject areas